Logo
x

Search

Subscribe Now

pfizer

Pfizer Reports the EC’s Conditional Approval of Durveqtix (Fidanacogene Elaparvovec) for the Treatment of Hemophilia B

Pfizer Reports the EC’s Conditional Approval of Durveqtix (Fidanacogene Elaparvovec) for the Treatment of Hemophilia B

  • July 26, 2024
Pfizer Reports Topline Data from P-III Trial of Giroctocogene Fitelparvovec for Treating Hemophilia A

Pfizer Reports Topline Data from P-III Trial of Giroctocogene Fitelparvovec for Treating Hemophilia A

  • July 24, 2024
Pfizer Reports the Advancement of Danuglipron Development

Pfizer Reports the Advancement of Danuglipron Development

  • July 11, 2024
Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19

Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19

  • June 28, 2024
Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy

Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy

  • June 13, 2024
Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)

  • June 3, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.